Clinical Trial Update: A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase II trial evaluating weekly bortezomib with Tositumomab and I-131 in relapsed or refractory follicular non-Hodgkin's lymphoma has terminated with posted re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• I-131 (I-131)
• Tositumomab (tositumomab)

Snippet

Sponsor: Rush University Medical Center | Conditions: Follicular Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2021-11-04